This ad will auto close in 10 seconds

GSK's new female CEO to get 25% less after pay policy review

Walmsley, who takes over next month, will be paid a base salary of 1,003,000 pounds ($1.23 million), or 10 percent less than outgoing CEO Andrew Witty.

GlaxoSmithKline picks insider Emma Walmsley as new CEO

GlaxoSmithKline picks insider Emma Walmsley as new CEO

GlaxoSmithKline said on Tuesday it had chosen Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates.

GSK sells anaesthetics to Aspen for up to $370 million

GSK sells anaesthetics to Aspen for up to $370 million

GlaxoSmithKline is to sell its portfolio of anaesthetic drugs to South Africa`s Aspen Pharmacare for up to 280 million pounds ($372 million) as part of a drive by the British drugmaker to focus on core therapy areas.

GlaxoSmithKline, Alphabet create $715 million bioelectronics firm

GlaxoSmithKline and Alphabet`s life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a new field of medicine known as bioelectronics.


GSK gets EU approval for first gene therapy for children

The world`s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes.

GlaxoSmithKline CEO Witty to bow out in March 2017

Witty, a 31-year company veteran, has been under fire from some investors in the past three years as sales and profits have flagged. His reputation was further tarnished by a damaging bribery scandal in China.

Popular antidepressant neither safe nor effective for teens

Depressed teens shouldn't take the widely used antidepressant paroxetine as it is neither safe nor effective, as per a reanalysis of an influential study originally published in 2001.

GlaxoSmithKline appoints Annaswamy Vaidheesh as MD

He would succeed current MD Hasit Joshipura, who is leaving office on August 1, 2015, the company said in a statement.

China deports British investigator, wife in GSK case

Chinese authorities on Wednesday deported a British investigator and his wife linked to a corruption case involving pharmaceutical giant GlaxoSmithKline (GSK), after releasing them from jail over a week ago, family sources told AFP.

CCI imposes Rs 64 crore fine on GlaxoSmithKline, Sanofi

Every year, the government invites tenders for purchase of meningitis vaccine that is required to be administered upon Haj pilgrims.

GlaxoSmithKline targets growth across units, scraps ViiV listing

GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth.

New-look GSK bets on consumer health spending

GSK predicted on Wednesday its consumer health sales would grow at a mid-single-digit compound annual rate over the next five years, slightly ahead of overall company sales.

Glaxo gets OK to expand marketing of inhaler drug

GlaxoSmithKline plc says it has received US approval to sell its once-a-day respiratory inhaler Breo Ellipta for a new use in asthma patients ages 18 and older.

Lupin ties up with Poland-based firm for generic asthama drug

Drug major Lupin has inked a pact with Poland-based Celon Pharma to jointly develop and market a generic version GlaxoSmithKline's Advair Diskus, a drug used to treat asthama, in global markets.

EU puts conditions on deals involving Novartis, GSK

The European Union on Wednesday approved mega deals involving drugmakers Novartis of Switzerland and GlaxoSmithKline of Britain, provided they sell off assets in the vaccines and consumer health businesses.

More unit IPOs an option for evolving GlaxoSmithKline

GlaxoSmithKline could consider more partial public share offerings for component units as it evolves in the coming years, potentially pointing to a break-up of the group if this offers value to shareholders.

Novartis okays OTC unit sale to GSK Consumer for Rs 109.7-cr

Novartis India's board on Tuesday approved the sale of its OTC division to GlaxoSmithKline Consumer Pvt Ltd, a consumer healthcare joint venture between Novartis AG and GSK, for a consideration of Rs 109.7 crore.

Novartis shares up nearly 2% at close

Surrendering most of early gains in-line with a weak stock market, shares of Novartis India ended nearly 2 percent higher Wednesday, a day after fair trade regulator CCI approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis.

GSKCH picks Zubair Ahmed for global role in JV with Novartis

The company said it would make a separate announcement of the organisational structure under Ahmed.

After China, GlaxoSmithKline faces pressure for change

GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back sceptical investors.